Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CLARITHROMYCIN Cause Malignant neoplasm progression? 11 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Malignant neoplasm progression have been filed in association with CLARITHROMYCIN (Clarithromycin). This represents 0.1% of all adverse event reports for CLARITHROMYCIN.

11
Reports of Malignant neoplasm progression with CLARITHROMYCIN
0.1%
of all CLARITHROMYCIN reports
1
Deaths
3
Hospitalizations

How Dangerous Is Malignant neoplasm progression From CLARITHROMYCIN?

Of the 11 reports, 1 (9.1%) resulted in death, 3 (27.3%) required hospitalization.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CLARITHROMYCIN. However, 11 reports have been filed with the FAERS database.

What Other Side Effects Does CLARITHROMYCIN Cause?

Drug ineffective (2,012) Nausea (1,597) Drug hypersensitivity (1,558) Drug interaction (1,288) Diarrhoea (1,228) Dyspnoea (1,151) Malaise (1,131) Headache (1,047) Off label use (944) Vomiting (921)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which CLARITHROMYCIN Alternatives Have Lower Malignant neoplasm progression Risk?

CLARITHROMYCIN vs CLARITIN CLARITHROMYCIN vs CLARITIN CHEWABLE CLARITHROMYCIN vs CLARITIN-D-12 CLARITHROMYCIN vs CLARITIN-D-24 CLARITHROMYCIN vs CLARITIN REDITABS

Related Pages

CLARITHROMYCIN Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression CLARITHROMYCIN Demographics